Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity
Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic.
Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Peramivir
- Zanamivir
- Other Drugs
- Influenza A
- Influenza B
- Influenza C
- Oral Administration
- Other Administration Routes
- Retail Pharmacy
- Hospital Pharmacy
- Clinics
- Online Stores
- Japan
- China
- South Korea
- Australia
- India
- Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF ASIA PACIFIC MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF ASIA PACIFIC MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF ASIA PACIFIC MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY
7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Asia Pacific Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Oseltamivir Phosphate
3.3 Baloxavir Marboxil
3.4 Peramivir
3.5 Zanamivir
3.6 Other Drugs
4 SEGMENTATION OF ASIA PACIFIC MARKET BY INFLUENZA TYPE
4.1 Market Overview by Influenza Type
4.2 Influenza A
4.3 Influenza B
4.4 Influenza C
5 SEGMENTATION OF ASIA PACIFIC MARKET BY ADMINISTRATION ROUTE
5.1 Market Overview by Administration Route
5.2 Oral Administration
5.3 Other Administration Routes
6 SEGMENTATION OF ASIA PACIFIC MARKET BY DISTRIBUTION CHANNEL
6.1 Market Overview by Distribution Channel
6.2 Retail Pharmacy
6.3 Hospital Pharmacy
6.4 Clinics
6.5 Online Stores
7 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY
7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
9 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Asia Pacific Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
LIST OF TABLES
Table 1. Snapshot of Asia Pacific Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Influenza Treatment Market
Table 3. Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. APAC Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. Japan Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. Japan Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. Japan Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. China Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. China Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. China Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. Australia Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. Australia Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. Australia Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. India Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 18. India Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 19. India Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 20. South Korea Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 21. South Korea Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 22. South Korea Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 23. Influenza Treatment Market in Rest of APAC by Country, 2019-2030, $ mn
Table 24. AstraZeneca Plc: Company Snapshot
Table 25. AstraZeneca Plc: Business Segmentation
Table 26. AstraZeneca Plc: Product Portfolio
Table 27. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 28. AstraZeneca Plc: Recent Developments
Table 29. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030
Table 30. Critical Success Factors and Key Takeaways
Table 1. Snapshot of Asia Pacific Influenza Treatment Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Influenza Treatment Market
Table 3. Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 4. Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, $ mn
Table 5. Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 6. Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 7. APAC Influenza Treatment Market by Country, 2019-2030, $ mn
Table 8. Japan Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 9. Japan Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 10. Japan Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 11. China Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 12. China Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 13. China Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 14. Australia Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 15. Australia Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 16. Australia Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 17. India Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 18. India Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 19. India Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 20. South Korea Influenza Treatment Market by Product Type, 2019-2030, $ mn
Table 21. South Korea Influenza Treatment Market by Administration Route, 2019-2030, $ mn
Table 22. South Korea Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn
Table 23. Influenza Treatment Market in Rest of APAC by Country, 2019-2030, $ mn
Table 24. AstraZeneca Plc: Company Snapshot
Table 25. AstraZeneca Plc: Business Segmentation
Table 26. AstraZeneca Plc: Product Portfolio
Table 27. AstraZeneca Plc: Revenue, 2016-2018, $ mn
Table 28. AstraZeneca Plc: Recent Developments
Table 29. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030
Table 30. Critical Success Factors and Key Takeaways
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Influenza Treatment Market
Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. Influenza Treatment Market in Japan, 2019-2030, $ mn
Figure 38. Influenza Treatment Market in China, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in Australia, 2019-2030, $ mn
Figure 40. Influenza Treatment Market in India, 2019-2030, $ mn
Figure 41. Influenza Treatment Market in South Korea, 2019-2030, $ mn
Figure 42. Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn
Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Influenza Treatment Market
Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)
Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn
Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn
Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, $ mn
Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, $ mn
Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, $ mn
Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)
Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, $ mn
Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, $ mn
Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, $ mn
Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue
Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)
Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, $ mn
Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn
Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue
Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)
Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn
Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn
Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, $ mn
Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, $ mn
Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue
Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 37. Influenza Treatment Market in Japan, 2019-2030, $ mn
Figure 38. Influenza Treatment Market in China, 2019-2030, $ mn
Figure 39. Influenza Treatment Market in Australia, 2019-2030, $ mn
Figure 40. Influenza Treatment Market in India, 2019-2030, $ mn
Figure 41. Influenza Treatment Market in South Korea, 2019-2030, $ mn
Figure 42. Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn
Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period
COMPANIES MENTIONED
AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited
